Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.
Yu-Wei Chen, Joanne Xiu, Kelsey Anne Poorman...
https://pubmed.ncbi.nlm.nih.gov/41785440/Actively Recruiting
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
474
Participants Needed
108
Research Sites
234 weeks
Total Duration
Researchers are evaluating the role of genetic testing in guiding targeted treatments for patients with castration-resistant prostate cancer that has spread. This phase II trial investigates whether assigning treatments based on DNA and RNA mutations found in cancer tissue can better control tumor growth. The study aims to measure tumor response, safety, progression-free survival, overall survival, and patient-reported outcomes among other clinical and molecular factors. Participants undergo genetic testing on previously collected tumor samples and are assigned to one of three treatment groups based on molecular tumor board decisions. Treatments include valemetostat tosylate taken orally daily in 28-day cycles carboplatin and cabazitaxel given intravenously every 21 days or physician-chosen regimens such as cabazitaxel alone, abiraterone acetate with prednisone orally, enzalutamide orally, or lutetium Lu 177 vipivotide tetraxetan intravenously every 42 days for up to six cycles. Throughout the trial, patients also receive regular MRI or CT scans, bone scans, and may opt for additional PET imaging and blood sample collections. During and after treatment, participants are closely monitored through imaging and laboratory tests to assess tumor response and side effects. After completing treatment, those without disease progression have follow-up visits every two months for six months, then every three months for up to five years. The study collects data on radiographic progression, survival, prostate-specific antigen changes, skeletal events, subsequent therapies, and adverse events. Patient experiences and molecular markers are also evaluated to understand treatment response and resistance.
CONDITIONS
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
R
Rana McKay, MD
S
Shiva Baghaie
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Valemetostat + genetic‑guided testing | Carboplatin + Cabazitaxel + genetic‑guided testing | Physician’s choice + genetic‑guided testing | Current standard‑of‑care for mCRPC |
|---|---|---|---|---|
| What it is | Experimental arm where patients undergo genetic testing and receive valemetostat tosylate based on molecular findings | Experimental arm where genetic testing guides assignment to carboplatin plus cabazitaxel | Experimental arm where genetic testing leads to physician‑chosen treatment | Common treatment options for mCRPC include androgen‑receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and PARP inhibitors |
| Role in the study | Assigned to receive valemetostat based on molecular profiling by a tumor board | Assigned to receive carboplatin plus cabazitaxel based on molecular profiling | Assigned to a treatment selected by the physician guided by molecular findings | Represents what patients would typically receive outside the trial after progression |
| Purpose or primary use | Investigational targeted therapy directed by genetic biomarkers | Investigational chemotherapy combination guided by molecular profile | Investigational arm where treatment is chosen by physician based on molecular findings | Current standard‑of‑care regimens aiming to control disease and extend survival |
| How it is administered or performed | Valemetostat tosylate administered orally after molecular testing | Carboplatin and cabazitaxel given intravenously following molecular assignment | Administration method varies by chosen therapy based on molecular results | Includes oral AR inhibitors, IV chemotherapy, radiopharmaceutical administration, or PARP inhibitors depending on agent |
| Evidence maturity or support | Efficacy and safety currently under investigation; no published results yet | Being evaluated; limited prior data in mCRPC background | Effectiveness varies by therapy chosen; not yet measured in this trial | Established survival benefits demonstrated in clinical trials |
| Important risks | Unknown; risk profile not yet established | Chemotherapy known to cause myelosuppression, neuropathy, and other toxicities | Safety depends on the therapy selected under physician guidance | Approved treatments carry known side effect profiles documented in clinical use |
| Important limitations | No outcome data yet; molecular targeting strategy unproven in mCRPC | Combination therapy’s benefit-risk balance in mCRPC remains exploratory | Heterogeneous treatments limit generalizability and comparison | Current options may eventually lose effectiveness due to resistance mechanisms |
| Potential patient impact | Unknown; impact dependent on trial outcomes | Uncertain; may offer benefit if trial shows efficacy | Variable; depends on chosen treatment and response | Known to extend survival and manage disease progression |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Varies by participant until disease progression or unacceptable side effects
Participants receive targeted treatments based on genetic testing. Treatments include oral valemetostat tosylate daily in 28-day cycles; intravenous carboplatin and cabazitaxel every 21 days; or physician-chosen regimens such as cabazitaxel alone, abiraterone acetate with prednisone, enzalutamide, or lutetium Lu 177 vipivotide tetraxetan every 42 days for up to six cycles. Imaging and scans are performed regularly throughout treatment.
Regular visits for treatment and imaging assessments
Duration - Up to 5 years
After completing treatment, participants without disease progression have follow-up visits every two months for six months, then every three months for up to five years to monitor health and cancer status.
Visits every 2 months for 6 months, then every 3 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yu-Wei Chen, Joanne Xiu, Kelsey Anne Poorman...
https://pubmed.ncbi.nlm.nih.gov/41785440/Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor